Closure of Biomedical Innovation Fund I

Wellington Management, one of the world’s largest independent investment management firms, today announced the final close of the oversubscribed Wellington Biomedical Innovation Fund I. The Fund will invest in private biotechnology companies that are focused on drug discovery and development, and are seeking capital to advance their scientific programs.

PRESS RELEASE

Wellington Management Announces Close of Biomedical Innovation Fund I at $393M

BOSTON, HONG KONG, LONDON, November 18, 2019 – Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the oversubscribed Wellington Biomedical Innovation Fund I (“Fund”).

The Fund will invest in private biotechnology companies focused on drug discovery and development, and seeking capital to advance their scientific programs.

Bob Deresiewicz, MD, Senior Managing Director at Wellington, said, “Biotechnology represents an exciting investment area, driven by an explosion in fundamental biomedical knowledge and a growing ability of companies to deploy that knowledge in the service of breakthrough drug discovery. We pursue an evidence-based approach to investing, seeking to leverage our biomedical, scientific, and industry expertise to identify promising assets that could meaningfully advance medical practice.”

Chris Kirk, the President of Wellington Alternative Investments, added, “This new sector-focused fund is the next step in expanding our private investment capabilities as we look for new opportunities to create long-term value for our investors. We believe our portfolio companies will benefit from partnering with Wellington and our extensive team of tenured industry analysts, who bring sector-level insights and public market expertise in support of their strategic growth plans.”

The close of Wellington’s Biomedical Innovation Fund I expands the Firm’s private investment platform, which now includes both health care and late stage growth funds totaling $2.7 billion. The funds’ global investor base includes public and private pension plans, insurance companies, corporations, and family offices.

About Wellington Management

Tracing its history to 1928, Wellington Management is one of the world’s largest independent investment management firms, serving as a trusted adviser to over 2,200 institutional and private clients located in more than 60 countries and managing over USD 1 trillion of assets.*

Wellington offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. The firm’s only business is investment management and its mission is to exceed the investment objectives and service expectations of its clients worldwide. Wellington’s solutions draw on a robust body of proprietary research and a collaborative culture that encourages independent thought and healthy debate.

For more information, visit wellington.com.

*For Wellington Management group of companies as at 30 September 2019.

Media
Prosek Partners (on behalf of Wellington Management)
Abby McAleney
[email protected]
(646) 503-6025

RECOMMENDED FOR YOU

Upgrading fintech infrastructure: Don’t forget the incumbents
We explore the fast-growing trend of upgrading fintech infrastructure, profile the key markets driving the opportunity, and share an example of the virtuous innovation cycle this technology can create.
December 2020
Upgrading fintech infrastructure: Don’t forget the incumbents
,
2021 Investment Outlook
As we head into the new year, thought leaders from across our investment platform share their views on pressing questions.
December 2020
2021 Investment Outlook
,
2021 Equity Outlook
In our 2021 Equity Outlook we offer our Fundamental Factor Team's latest insights, share multiple views on value investing, explore the latest opportunities in emerging markets post COVID, profile the increasing impact of innovation and technology, and outline Wellington’s growing ESG integration capabilities.
December 2020
2021 Equity Outlook
,
The future of alternative investments
Director of Alternatives Danny Sharp explores the future of alts — discussing dispersion in today's markets, the opportunities it presents, and the impact of the COVID-19 pandemic on the alternative investments landscape.
November 2020
The future of alternative investments
,
EMs: With great challenges come great opportunities
From health and wellness to climate change and more, the COVID-19 crisis has spawned or accelerated compelling investable themes across a range of EM countries. Against that backdrop, four of Wellington’s EM equity portfolio managers share their latest insights.
October 2020
EMs: With great challenges come great opportunities
,
Tracking the green transition in emerging markets
COVID-19 has ratcheted up environmental debates across emerging markets and highlighted the intersection of those concerns with local supply chains and infrastructure gaps. Equity Portfolio Manager Liliana Castillo Dearth looks at China as a case study.
October 2020
Tracking the green transition in emerging markets
,
The dawn of divergence and the art of subtlety
Multi-Asset Strategist Nick Samouilhan highlights the key divergences we should start to see as fundamental differences between companies, sectors, and countries begin to matter more.
October 2020
The dawn of divergence and the art of subtlety
,
Nick Samouilhan
 PhD, CFA, FRM
On the ground in emerging markets
Portfolio Manager Greg Mattiko profiles the COVID-19 pandemic’s varied outcomes on different emerging markets, explores the potential opportunities from falling correlations, and highlights the benefits of a global approach to emerging market investing.
September 2020
On the ground in emerging markets
,